The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer.
 
Li Zhang
Consulting or Advisory Role - AstraZeneca; Innovent Biologics
Research Funding - Akesobio (Inst); AstraZeneca (Inst); BMS (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); Junshi Pharmaceuticals (Inst); QiLu Pharmaceutical (Inst)
 
Yunpeng Yang
No Relationships to Disclose
 
Jian-ji Pan
No Relationships to Disclose
 
Xiaozhong Chen
No Relationships to Disclose
 
Yan Sun
No Relationships to Disclose
 
Hui Wang
No Relationships to Disclose
 
Shenhong Qu
No Relationships to Disclose
 
Nianyong Chen
No Relationships to Disclose
 
Lizhu Lin
No Relationships to Disclose
 
Siyang Wang
No Relationships to Disclose
 
Qitao Yu
No Relationships to Disclose
 
Guihua Wang
No Relationships to Disclose
 
Feng Lei
No Relationships to Disclose
 
Jiyu Wen
No Relationships to Disclose
 
Chenqi Chen
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Yanjie Wu
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Shiangjiin Leaw
Employment - BeiGene
Research Funding - BeiGene
 
Wenfeng Fang
No Relationships to Disclose